{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:16:05Z","timestamp":1780758965701,"version":"3.54.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0202439","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T13:45:47Z","timestamp":1538574347000},"page":"e0202439","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["Vancomycin associated acute kidney injury in pediatric patients"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2221-2069","authenticated-orcid":true,"given":"Brady S.","family":"Moffett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Galati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankhi","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Akcan-Arikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,10,3]]},"reference":[{"issue":"6","key":"ref1","first-page":"486","article-title":"Frequency of and Risk Factors for Acute Kidney Injury Associated With Vancomycin Use in the Pediatric Intensive Care Unit. The journal of pediatric pharmacology and therapeutics: JPPT: the official journal of","volume":"21","author":"S Bonazza","year":"2016","journal-title":"PPAG"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The Nephrotoxicity of Vancomycin","volume":"102","author":"EJ Filippone","year":"2017","journal-title":"Clinical pharmacology and therapeutics"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","article-title":"Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children","volume":"158","author":"S McKamy","year":"2011","journal-title":"The Journal of pediatrics"},{"issue":"9","key":"ref4","first-page":"379","article-title":"Vancomycin nephrotoxicity: myths and facts","volume":"69","author":"A Gupta","year":"2011","journal-title":"The Netherlands journal of medicine"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jpeds.2010.12.018","article-title":"Vancomycin nephrotoxicity may be overstated","volume":"158","author":"BS Moffett","year":"2011","journal-title":"The Journal of pediatrics"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/2042018816638223","article-title":"Review of vancomycin-induced renal toxicity: an update","volume":"7","author":"O. Bamgbola","year":"2016","journal-title":"Therapeutic advances in endocrinology and metabolism"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5863\/1551-6776-21.1.66","article-title":"Vancomycin Dosing and Pharmacokinetics in Postoperative Pediatric Cardiothoracic Surgery Patients","volume":"21","author":"EC Benefield","year":"2016","journal-title":"The journal of pediatric pharmacology and therapeutics: JPPT: the official journal of PPAG"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/pbc.22601","article-title":"Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study","volume":"55","author":"BT Fisher","year":"2010","journal-title":"Pediatric blood & cancer"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5863\/1551-6776-21.2.169","article-title":"Acute Kidney Injury in a Child Receiving Vancomycin and Piperacillin\/Tazobactam","volume":"21","author":"BW Ibach","year":"2016","journal-title":"The journal of pediatric pharmacology and therapeutics: JPPT: the official journal of PPAG"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ppul.23718","article-title":"Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients","volume":"52","author":"LK LeCleir","year":"2017","journal-title":"Pediatric pulmonology"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1111\/chd.12187","article-title":"Vancomycin-associated acute kidney injury in pediatric cardiac intensive care patients","volume":"10","author":"BS Moffett","year":"2015","journal-title":"Congenital heart disease"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/jpids\/pit076","article-title":"Are Elevated Vancomycin Serum Trough Concentrations Achieved Within the First 7 Days of Therapy Associated With Acute Kidney Injury in Children?","volume":"3","author":"CA Knoderer","year":"2014","journal-title":"Journal of the Pediatric Infectious Diseases Society"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2215\/CJN.05431207","article-title":"Ascertainment and epidemiology of acute kidney injury varies with definition interpretation","volume":"3","author":"M Zappitelli","year":"2008","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2215\/CJN.11011016","article-title":"Vancomycin and the Risk of AKI: Now Clearer than Mississippi Mud","volume":"11","author":"TD Nolin","year":"2016","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"key":"ref15","article-title":"Doses, durations, and gender predict vancomycin-induced kidney injury in pre-clinical studies","author":"JN O'Donnell","year":"2017","journal-title":"International journal of antimicrobial agents"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jhm.946","article-title":"Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans","volume":"7","author":"KK Prabaker","year":"2012","journal-title":"Journal of hospital medicine"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.amjmed.2010.07.025","article-title":"Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity","volume":"123","author":"L Pritchard","year":"2010","journal-title":"The American journal of medicine"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1177\/1060028014549185","article-title":"Factors associated with acute kidney injury in children receiving vancomycin","volume":"48","author":"EA Sinclair","year":"2014","journal-title":"The Annals of pharmacotherapy"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"SJ van Hal","year":"2013","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000452430","article-title":"Vancomycin Trough Levels: Cause or Result of Acute Kidney Injury?","volume":"44","author":"WM Bennett","year":"2016","journal-title":"American journal of nephrology"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000452427","article-title":"Vancomycin Trough and Acute Kidney Injury: A Large Retrospective, Cohort Study","volume":"44","author":"K Hammoud","year":"2016","journal-title":"American journal of nephrology"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/INF.0000000000000991","article-title":"Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome","volume":"35","author":"JC McNeil","year":"2016","journal-title":"The Pediatric infectious disease journal"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/j.ajkd.2015.07.019","article-title":"Acute Kidney Injury Incidence in Noncritically Ill Hospitalized Children, Adolescents, and Young Adults: A Retrospective Observational Study","volume":"67","author":"TL McGregor","year":"2016","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.01900214","article-title":"AKI in hospitalized children: comparing the pRIFLE, AKIN, and KDIGO definitions","volume":"10","author":"SM Sutherland","year":"2015","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1611391","article-title":"Epidemiology of Acute Kidney Injury in Critically Ill Children and Young Adults","volume":"376","author":"A Kaddourah","year":"2017","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijantimicag.2017.02.023","article-title":"Acute kidney injury risk associated with piperacillin\/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function","volume":"50","author":"N Jeon","year":"2017","journal-title":"International journal of antimicrobial agents"},{"issue":"21","key":"ref27","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2016.6361","article-title":"Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988\u20131994 Through 2013\u20132014","volume":"315","author":"CL Ogden","year":"2016","journal-title":"Jama"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"GJ Schwartz","year":"2009","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1177\/1060028015594190","article-title":"Late-Occurring Vancomycin-Associated Acute Kidney Injury in Children Receiving Prolonged Therapy","volume":"49","author":"CA Knoderer","year":"2015","journal-title":"The Annals of pharmacotherapy"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1089\/sur.2014.198","article-title":"Vancomycin-Associated Nephrotoxicity: The Obesity Factor","volume":"16","author":"SW Davies","year":"2015","journal-title":"Surgical infections"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/0009922810393500","article-title":"Vancomycin dosing in obese pediatric patients","volume":"50","author":"BS Moffett","year":"2011","journal-title":"Clinical pediatrics"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1097\/CCM.0000000000000514","article-title":"Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*","volume":"42","author":"TP Hanrahan","year":"2014","journal-title":"Critical care medicine"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/0310057X1504300507","article-title":"Factors associated with vancomycin nephrotoxicity in the critically ill","volume":"43","author":"TP Hanrahan","year":"2015","journal-title":"Anaesthesia and intensive care"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1053\/j.ajkd.2014.10.018","article-title":"Risk factors for acute kidney injury in older adults with critical illness: a retrospective cohort study","volume":"65","author":"SL Kane-Gill","year":"2015","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","author":"J Le","year":"2013","journal-title":"The Pediatric infectious disease journal"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40272-016-0205-1","article-title":"Identifying High-Risk Medications Associated with Acute Kidney Injury in Critically Ill Patients: A Pharmacoepidemiologic Evaluation","volume":"19","author":"MB Slater","year":"2017","journal-title":"Paediatric drugs"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/INF.0000000000000748","article-title":"Fever and Reversible Laboratory Abnormalities Associated with Prolonged Use of Piperacillin-Tazobactam in Children","volume":"34","author":"A Patel","year":"2015","journal-title":"The Pediatric infectious disease journal"},{"issue":"12","key":"ref38","doi-asserted-by":"crossref","first-page":"e173219","DOI":"10.1001\/jamapediatrics.2017.3219","article-title":"Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin\/Tazobactam Treatment Among Hospitalized Children","volume":"171","author":"KJ Downes","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","article-title":"Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis","volume":"46","author":"MK Luther","year":"2018","journal-title":"Critical care medicine"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/jac\/25.4.679","article-title":"Nephrotoxicity of vancomycin, alone and with an aminoglycoside","volume":"25","author":"MJ Rybak","year":"1990","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"F236","DOI":"10.1136\/archdischild-2015-308459","article-title":"A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates","volume":"101","author":"JE Constance","year":"2016","journal-title":"Archives of disease in childhood Fetal and neonatal edition"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00134-002-1346-y","article-title":"Low-dose dopamine: a systematic review","volume":"28","author":"PE Marik","year":"2002","journal-title":"Intensive care medicine"},{"issue":"9248","key":"ref43","first-page":"2139","article-title":"Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial","volume":"356","author":"R Bellomo","year":"2000","journal-title":"Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet (London, England)"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.7326\/0003-4819-142-7-200504050-00010","article-title":"Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death","volume":"142","author":"JO Friedrich","year":"2005","journal-title":"Annals of internal medicine"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/PCC.0b013e3181728c25","article-title":"Renal effects of fenoldopam in critically ill pediatric patients: A retrospective review","volume":"9","author":"BS Moffett","year":"2008","journal-title":"Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies"},{"issue":"6","key":"ref46","doi-asserted-by":"crossref","first-page":"e1469","DOI":"10.1097\/MJT.0000000000000147","article-title":"Comparison of Arginine Hydrochloride and Acetazolamide for the Correction of Metabolic Alkalosis in Pediatric Patients","volume":"23","author":"DE Heble Jr.","year":"2016","journal-title":"American journal of therapeutics"},{"issue":"4","key":"ref47","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2215\/CJN.08110910","article-title":"Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children","volume":"6","author":"BS Moffett","year":"2011","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0202439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T05:01:03Z","timestamp":1571979663000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0202439"}},"subtitle":[],"editor":[{"given":"Zaccaria","family":"Ricci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,3]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0202439","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,3]]}}}